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Problems associated with cell culture are frequently ignored by the
biomedical community, both in academic research and in the
biotechnology and pharmaceutical industries. With depressing
regularity, scientific data have to be retracted or modified because
of cross-contamination between cell lines. Occult contamination
with microorganisms (especially mycoplasma) and phenotypic
drift due to serial transfer between laboratories are frequently
encountered. Whatever the nature of the cell culture operation,
large or small, academic or commercial, such problems can occur.
The aim of these guidelines is to highlight these problems and
provide recommendations as to how they may be identified,
avoided or where possible eliminated.
The guidelines are meant to provide a series of pertinent and
accessible reminders, which should be of benefit both to those for
whom using cell lines is a new skill and those who may, despite
years of experience, have allowed suboptimal procedures to
become part of local practice. The guidelines are not meant to
substitute for the many excellent textbooks which provide detailed
information on many aspects of cell culture techniques and
procedures.
Definitions of some terms frequently used in tissue culture are
given in Appendix 1.
SECTION 1: DERIVATION OF A NEW CELL LINE
Ethical and legal issues
Ethical approval for the use of human tissue
These guidelines stress the responsibility of the researcher to the
donor. Before any material can be collected from a hospital
patient, ethical approval for the research must be obtained from the
NHS Trust concerned. Therefore the Local Research Ethics
Committee (LREC) should be consulted at an early stage. Grant-
giving bodies usually will not fund projects involving patient
material without the prior consent of the appropriate LREC.
The LREC form will usually request details of (a) the project
(objectives, description, scale, duration), (b) those responsible for
its supervision, sponsorship and the recruitment and selection of
subjects, (c) the procedures and risks involved (both to the patients
and those undertaking the research) and (d) the form of written
consent to be obtained from the patient or relatives (see Appendix
2). The LREC must be informed of any involvement of a commer-
cial company and the appropriate licensing of its products and
equipment. LRECs have not usually been concerned with intellec-
tual property rights but, with the increasing commercialization
of research, this attitude may change. The NHS Trust will be
interested in any commercial benefits arising from the research
and usually will require that any additional costs incurred by the
hospital as a result of the research are reimbursed.
Ethics committees are concerned that patient care and diag-
nostic needs are not compromised by the diversion of material for
research purposes. It is recommended that clinicians are members
of the team undertaking the study. Research may normally be
conducted on tissue or specimens that are removed for the benefit
of the patient and are surplus to diagnostic requirements. The
removal of body fluids which are accessible with minimal inva-
sion (e.g. blood, semen, urine, sweat, saliva) usually can be
justified. However, if additional tissue is required, there must be a
strong justification and the patient must be counselled accordingly.
Informed consent
The study of cells or DNA from patients has often, in the past,
been regarded as an extension of the diagnostic process into
research. It used to be accepted that the patient did not need to be
consulted about the use of tissue surplus to clinical requirements.
Attitudes have changed, and LRECs will generally require that the
patient is asked for consent for tissue to be used for research
purposes (see Appendix 2). In some circumstances (e.g. when
additional tissue is required or a commercial waiver is requested),
the LREC may require that the patient is informed in greater detail
about the nature and purposes of the research.
Attitudes to the use of tissue from patients for research have
also changed for another reason. Tissue derived from a patient
may give rise, directly or indirectly, to a cell line or other product
of commercial value. If the researcher wishes to control such
financial benefit, then it will also be necessary to ask the patient to
waive any right to the tissue or its exploitation.
Ethics Committees will need evidence that patient confiden-
tiality will be maintained, including any personal data derived
from the research, by coding the sample such that only clinical
staff are aware of the patient’s identity. If this confidentiality is to
be broken, e.g. for familial studies, additional authority will be
required.
UKCCCR Guidelines for the Use of Cell Lines in
Cancer Research
UKCCCR, PO Box 123, Lincoln’s Inn Fields, London WC2A 3PX, UK
1495
Correspondence to: The Secretariat, UKCCCR, PO Box 123, Lincoln’s Inn
Fields, London WC2A 3PX, UK
British Journal of Cancer (2000) 82(9), 1495–1509
© 2000 Cancer Research Campaign
DOI: 10.1054/ bjoc.1999.1169, available online at http://www.idealibrary.com on 
These Guidelines were prepared for the UKCCCR during 1998 by an ad hoc
committee comprising:
Dr J R W Masters (University College London, Chairman), Dr P Twentyman
(UKCCCR Secretariat, London, Secretary), Dr C Arlett (MRC Cell Mutation Unit,
Sussex), Mr R Daley (Sigma-Aldrich Company Ltd, Poole), Dr J Davis
(Bio-Products Laboratory, Elstree), Dr A Doyle (Centre for Applied Microbiology
and Research, Salisbury). Dr S Dyer (Medical Research Council, London),
Dr I Freshney (University of Glasgow), Dr A Galpine (Cancer Research Campaign,
London), Ms M Harrison (Imperial Cancer Research Fund, London), Dr H Hurst
(ICRF Molecular Oncology Unit, Hammersmith Hospital), Dr L Kelland (Institute
of Cancer Research, Sutton), Dr G Stacey (National Institute for Biological
Standards and Control, South Mimms), Professor I Stratford (University of
Manchester), Dr T H Ward (Paterson Institute for Cancer Research, Manchester)Ownership and patent rights
There is a long list of people and organizations who might lay
claim to the ownership of specimens and their derivatives,
including the donor and relatives, the surgeon and pathologist, the
hospital authority where the sample was taken, the scientists
engaged in the research, the institution where the research work
was carried out, the funding organization supporting the research
and any collaborating commercial company.
The ultimate control of subsequent ownership and patent rights
will need to be negotiated between the research coordinator, the
host institution, the funding organization and the commercial
company. Most universities and research institutes have an office
which deals with such negotiation, as do most of the larger funding
agencies.
Ethical approval for the use of animal tissue
It is essential that all legislation relating to the use of laboratory
animals in scientific procedures is considered and that any neces-
sary documentation is available, as described in the UKCCCR
Guidelines for the Welfare of Animals in Experimental Neoplasia
(1998). Some institutions have Animal Welfare Committees that
act as Ethics Committees for research involving animals and
specific approval from such a committee may be necessary.
Material transfer agreements
Distribution of cell lines should be regulated by the originating
laboratory or by a cell bank authorized by the originator. This will
minimize successive transfers between laboratories and the resul-
tant risks of cross-contamination and phenotypic drift (see Section
2). Ownership rights and exploitation should be covered in a
Materials Transfer Agreement, signed by the host institution and
the recipient before the cell line is transferred. The recipient
should receive a signed statement indicating that ethical approval
and informed consent has been received in respect of those cells.
The donating institution may wish to state that no liability can be
accepted for any problem arising from the use of the cells and that
no guarantee of freedom from infective agents can be given. If a
recipient of a cell line derives a subline by cloning and/or genetic
manipulation, a new agreement of ownership will need to be
established and this proviso should be contained in the Materials
Transfer Agreement.
Restrictions on the use of cell lines should be minimal, but it is
reasonable to insist on acknowledgement, and even co-authorship
where the originating laboratory makes a substantial contribution
to the subsequent work. However, merely supplying a cell line
would not in itself normally warrant co-authorship of a paper
describing work carried out using the line. The agreement should
indicate that the cells must not be passed on to another laboratory
or used for commercial exploitation.
Authentication and characterization
Deriving a new human cell line is an expensive and time-
consuming exercise. The subsequent value of the new cell line
will depend on the ability to authenticate its origin and on the
associated information that is available.
Tissue
In addition to the tissue used to derive the cell line, it is also
recommended for authentication that additional material is stored
for:
a. CONFIRMATION OF ORIGIN. A small portion of the sample
being used to originate the culture (or derived DNA or a blood
sample) should be frozen or processed immediately for subse-
quent confirmation that any eventual cell line is derived from
that patient (DNA fingerprinting or profiling is recommended
for confirmation of origin)
b. CONFIRMATION OF DIAGNOSIS. A small portion of the
sample being used to originate the culture should be removed
and sent for histopathological confirmation. This is particu-
larly important if the sample is supplied directly by the
clinician, as it may not be representative of the tissue sent to
the histopathologist for routine reporting – for instance it may
be at some distance from a tumour and lack cancer cells
c. NORMAL TISSUE FOR COMPARISON. A small quantity of
blood (e.g. 10 ml) or normal tissue should be frozen for
comparative purposes (e.g. for analysis of loss of heterozy-
gosity). This can also be used for authentication of the origin
from that patient if necessary.
Clinical information
As much of the following information as possible should be
recorded, the first 4 items being of particular importance:
a. Age and gender of patient
b. Hospital and pathology numbers
c. Site of origin and nature of tissue specimen
d. Evidence of informed consent and waiver of commercial rights
by donor
e. Histopathology report
f. Clinical history, treatment and subsequent course of disease
g. Additional information concerning stage of disease, tumour
marker status and molecular genetics, etc.
Accessory information
It is recommended that a complete record of the details concerning
cell culture are kept, at least up to the point when the cell stocks are
banked, including the type, sources and batch numbers of all media
and additives and the methods by which the cell line was estab-
lished. It is helpful to record the split ratios and the passage number.
A description of the cell type is helpful, e.g. epithelial-or fibro-
blast-like. When definitive characterization has been performed,
this becomes epithelial or fibroblastic and the tissue type may be
defined where specific markers are available. The transformation
status of the cell line should be recorded as finite or continuous,
normal or transformed and any special properties described such
as growth capacity as a xenograft.
If a cell line has been genetically modified, it is necessary to
describe the process used, including details of sequences and mode
of insertion. For recombinant cell lines, additional information is
needed, and additional tests are necessary to demonstrate lack of
infectivity (e.g. following the use of retrovirus). For hybridomas,
details of the sources of both sets of cells are needed. Where
animal tissue is used to originate a culture, it is important to record
the species and strain, age, gender and genetic status.
Although it may be necessary to use antibiotics in the primary
culture, they should be removed as soon as possible and the cells
tested for mycoplasma after a period of at least 2 weeks in
antibiotic-free medium. The type of assay used for mycoplasma
detection should be stated (see Section 4, Mycoplasma
Contamination), as should the frequency and date of the last test.
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It is essential that the designation of the cell line is unambiguous. It
should be unique and should maintain donor anonymity. The
format could be as follows: Institution – Source or series – code
or log number – clone number; e.g. MOG-G123-D4 (Medical
Oncology Glasgow – Glioma Cell line 123 – clone D4). The full
designation should be used in publications.
If the cell line is obtained from another source, its original
designation must be retained. If obtained from a cell bank, its
accession number should be quoted in publications. Genetic modi-
fications, sublines and clones should be indicated by a suffix,
following the original designation. It is important that the designa-
tion is unique so that there is no ambiguity with other cell lines or
biological resources during literature searches.
Publication
All first publications should include all the information described
in the previous sections and subsequent publications should cite
the first publication. Every publication should confirm that the
cultures have been tested for mycoplasma using a sensitive
method, and confirming that the test is negative. The first publica-
tion should also provide evidence that the cells have been derived
from the individual claimed to be the source. Some journals insist
on cell lines being made available as a condition of publication,
so that other laboratories can repeat the work. Information on
deposits in cell banks or whom to contact to obtain cells is helpful
in this regard. Publication of work with the cell line implies its
entry into the public domain and the right of others to acquire the
cell line from the originator or the nominated cell bank.
SECTION 2: CELL LINE ACQUISITION
Whilst the problems of cross-contamination, microbial contamina-
tion and phenotypic drift can occur in the laboratory of origin,
these are more likely to arise during the serial transfer of cell
lines among other laboratories. It is therefore necessary to make
appropriate checks whenever a new cell line is acquired.
Checking a cell line new to the laboratory
Characterization is essential not only when deriving new lines, but
also when a cell line is obtained from a cell bank or other labora-
tory. A published description of a cell line with a certain property
is no guarantee that it is still the same line or has the same
properties. Enormous amounts of time and effort have been wasted
by scientists using cross-contaminated cell lines which are either
of a different species or cell of origin to that claimed, or cell
lines which are contaminated with mycoplasma or some other
microorganism.
Quarantine
Cell lines new to a laboratory should be quarantined; i.e. kept
entirely separate from existing cell line stocks. Ideally, a separate
quarantine laboratory should be available for this purpose. The
next best approach is to have a Class II microbiological safety
cabinet (MSC) and an incubator dedicated for quarantine. If this is
not possible, other steps should be taken to minimize the risk of
contamination, including (a) cells in quarantine should be handled
only after all the other cell culture has been completed that day, (b)
the new cultures should be placed in a dedicated incubator or a
sealed container before going into a general incubator, (c) the
MSC should be cleaned after use with a suitable disinfecting agent
(such as 5% Dettol in 70% ethanol) and run for at least another
5 min prior to shutdown.
Cells should be quarantined until the origin of the cells has been
authenticated or a DNA fingerprint or profile defined and it is
confirmed that they are negative for microorganisms.
Characterization
DNA fingerprinting or profiling are the recommended methods for
confirming the origin of a cell line and to check for cross-contam-
ination between cells. Ideally it will be possible to compare the
DNA with that of the tissue of origin. Unfortunately this is only
possible in a minority of the cell lines already available.
Nevertheless, it is desirable that a DNA fingerprint or profile is
defined before the cell line is used, so that at least it can be distin-
guished from other cell lines in the same laboratory and other
common cross-contaminants and can, therefore, be tracked
through subsequent transfers.
As a minimum safeguard against microbial contamination,
screening for mycoplasma is essential before the cell line leaves
quarantine.
Where possible, new cell stocks should be characterized for
features which will enable monitoring of genotype and phenotype
variability. These include the karyotype (by G-banding or fluores-
cence in situ hybridization) and production of cell or tissue
specific markers (e.g. cell surface markers and intermediate
filament proteins such as cytokeratins for epithelial cells, glial fib-
rillary acidic protein for astroctyes, prostate-specific antigen, etc.).
It is helpful to measure under defined conditions features such
as population doubling time, colony forming efficiency,
morphology under phase contrast during both exponential and
plateau-phase growth (with photographs) and the histopathology
of xenografts in immune-deficient mice.
Sources of cell lines
Acquisition of cell lines presents a number of potential hazards.
Cell lines may simply not be what they are claimed to be. In the
past, many cell lines have been passed from laboratory to labora-
tory with a range of labels and turned out to be something
completely different. This is still happening with unnecessary
frequency. Human cell lines may carry viral contamination such as
hepatitis or HIV, representing a health hazard to laboratory
workers (see Section 3, Safety). They may be contaminated with
bacteria, fungi, mycoplasma, or viruses, which may spread to other
cell lines.
The more laboratories that a cell line has passed through since
its origin, characterization and contamination testing, the less
reliance should be placed on its documented properties. However,
even the originator as source is not a guarantee of authenticity. If
the receiving laboratory wishes to place any reliance on historic
data obtained with a cell line, it should always carry out its own
testing procedures (as described in Section 2, Characterization)
before accepting an incoming cell line into general use.
Cell culture banks
A number of ‘culture collections’ or ‘cell banks’ have been estab-
lished by either academic or commercial bodies (see Appendix 3
for web sites). The prototype was the American Type Culture
Collection (ATCC) currently holding over 14 000 cell lines. Other
major collections are the European Collection of Animal Cell
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Collection (DSMZ), Coriell Repositories, Camden, NJ and the
Japanese Culture Collections (RIKEN and JCRB). Cell lines from
these sources are unlikely to be contaminated with microorgan-
isms, unless so stated in the accompanying literature. However,
some of these cell lines have been acquired following multiple
transfer between laboratories, so authenticity is not guaranteed
unless specifically stated.
SECTION 3: CELL LINE PRACTICE
Detailed information on methodology can be found in a number of
text books, including Basic Cell Culture by John Davis, IRL Press,
1994 and Culture of Animal Cells by Ian Freshney, 3rd edition,
Wiley-Liss, 1994.
Safety
Cell culture in the commercial sector is subject to regulation. For
example, where cell culture products are to be used by the pharma-
ceutical industry, Good Manufacturing Practice (GMP) (HMSO,
1997) must be complied with, along with the more specific guid-
ance contained in a number of other documents issued by the
European Union, the US Food and Drug Administration and the
International Conference on Harmonisation (ICH). These guide-
lines on cell culture are in addition to local and national safety
regulations, and do not replace rules of safety within individual
laboratories, as these vary according to local circumstances. The
advice of the local Biological Safety Officer should be sought
where there is any doubt about the introduction of new materials
or procedures.
Employers are responsible for employee safety under the Health
and Safety at Work Regulations by providing information, instruc-
tion and training and effective protection against hazard in the
workplace. The most relevant component is the COSHH (Control
of Substances Hazardous to Health) regulations (Health and Safety
Commission, 1994). These regulations foster safe working prac-
tices by establishing that any proposed procedure is both justifi-
able and safe by requiring that a risk assessment is made before
work is started. The COSHH regulations also set out a duty for
employees to collaborate fully so that employers can meet the
legal obligations. The risk assessment must be approved by the
local authorized Biological Safety Officer. It should deal with the
entire process and not just individual hazardous chemicals and
biological agents. Risk assessments should not be copied from
one laboratory to another since the same hazards represent
different risks according to local conditions and the scale of the
operation.
The main safety hazard arising from cell culture is from
agents carried either by the cells or from the components of the
culture medium. Cells can carry viruses and at least one fatality
due to a viral infection acquired from cells has been reported
(Hummeler et al, 1959). Serum could also contain a variety of
microorganisms, including viruses and mycoplasma.
Using body fluids or cells derived from laboratory staff for
research purposes is not recommended. The use of blood or tissue
from laboratory staff for the development of transformed cell lines
is prohibited, as the person concerned would have no immunity to
the transformed cells.
Clinical specimens
Advice on dealing with blood and HIV-infected material is
contained in the guidelines from the Health and Safety Executive
(HSE) (HMSO, 1996). Material with a high potential risk of infec-
tion should be excluded or handled appropriately. All samples of
blood, body fluids, secretions, tissues and cells are potentially
infectious. Risk of exposure to infection can be minimized by
avoiding the use of ‘sharps’ (such as needles and blades) and any
items or processes likely to create aerosols. When taking blood,
the needle should be removed from the syringe and discarded
safely into a ‘sharps’ container, before the specimen is transferred.
Primary cultures
There are documented cases of serious laboratory-acquired infec-
tions (e.g. hantavirus, lymphocytic choriomeningitis virus) from
tissue, primary cell cultures and tumour cells taken from, or trans-
planted into, rodents (Lloyd and Jones, 1984). When obtaining
primary tissue from laboratory animals it is important to ensure
that the animals used are free of specific pathogens and suppliers
should provide evidence of testing. This information should be
used in risk assessments and cross-referenced in laboratory record
books where the respective primary cells are used.
Continuous cell lines
The extensive use of continuous cell lines indicates that there is
little risk from routine cell culture. However, since most cell lines
are not fully characterized it is wise to regard all such material as
potentially infectious. A tumour grew in a laboratory worker acci-
dentally inoculated with cells of a human tumour cell line through
a needle (Gugel and Sanders, 1986) and cancers have been trans-
ferred between people during transplantation (Southam, 1958).
Although the growth of tumour cells from a different person is
unlikely in healthy individuals, anyone with a compromised
immune system is at greater risk.
Genetically modified cells
The introduction of genes can reactivate dormant infectious agents
in the host cell or create new agents by recombination. Viral
vectors that can infect human cells (e.g. amphotropic retroviruses)
are particularly dangerous. Recommended procedures for creation,
use, storage, transportation and disposal of genetically modified
organisms, including modified cell lines, are given in the
Genetically Modified Organisms (Contained Use) Regulations
(Health and Safety Commission, 1992) (NB: These do not apply to
construction of somatic cell hybrids). These regulations describe
how to make a full risk assessment which must receive approval
from the Local Genetic Modification Safety Committee, and in
certain cases specific approval from the HSE may be required.
Genetically modified cells may require special conditions. For
example, selective pressure may need to be maintained on trans-
fectants to retain the genetic modification, and the pressure may
need to be maintained during storage. Distribution of genetically
modified cells may be subject to regulation, depending on the
modification.
Containment
Containment level 2 is the minimum requirement for manipulating
human cancer cell lines and is described in the Advisory
Committee on Dangerous Pathogens (ACDP) guidelines (HMSO,
1995). This level of containment is also applicable to untested cell
products, such as monoclonal antibody-containing supernatants or
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that all subculture, or other procedures involving the manipulation
of bulk cells, should be performed in a Class II Microbiological
Safety Cabinet (MSC). Laminar flow devices other than MSC
should not be used for cell culture. Horizontal flow cabinets,
where the airflow is directed at the operator, are particularly
hazardous and must never be used when working with cells or
potentially infectious cell derivatives.
The spread of infection often occurs via contaminated aerosols
and any process which produces aerosols from crude cell culture
preparations is a potential source of infection. Such processes (e.g.
centrifugation, tissue disaggregation, vortex mixing) should be
contained or the material rendered harmless before it is processed.
Special guidelines for the safe use of flow cytometers with unfixed
cells have been published by the International Society for
Analytical Cytology (Schmid et al, 1997).
Disposal
Control of the disposal of laboratory waste should prevent expo-
sure of staff and environment to infectious hazards and prevent
contamination. The Environmental Protection Act 1990 and the
Environmental Protection Act Part II, The Special Waste
Regulations 1996 (copies available from The Stationery Office,
PO Box 276, London SW8 5DT) define clinical waste and appro-
priate procedures for its collection and disposal. Those producing
clinical waste (including drugs, pharmaceuticals, animal and
human material and any items contaminated with these materials)
have a duty in law to ensure its safe disposal. All infected waste
arising from work in laboratories should be made safe to handle by
appropriate means (e.g. autoclaving), before disposal by incinera-
tion. Details of recommended procedures are given in HSE
guidelines (Health Services Advisory Committee, 1992).
Training
Trainees need to learn the theory, dangers and safety measures of
cell culture before starting in the laboratory. Practical training is
best carried out on a one-to-one basis, with extensive reference
made to any relevant Standard Operating Procedure (SOP). As
compliance with any demanding technique tends to decrease
with time and familiarity, performance should continue to be
monitored.
Individuals experienced in cell culture starting in a new labora-
tory should read the protocols specific to the laboratory, such as
safety, waste disposal, autoclaving, incubator use/sharing,
labelling of cultures and medium storage.
Storage and banking
The first step to ensuring a reliable and reproducible supply of
cells is the establishment of a Master Cell Bank of 10–20
ampoules. One ampoule from the Master Cell Bank is used to
generate a Working Cell Bank or Distribution Cell Bank (Stacey
and Doyle, 1997). The Working Cell Bank contains sufficient
ampoules to provide at least one ampoule for every 3 months of
the proposed experimental period plus sufficient ampoules for
contingencies and distribution. Incorrect or serial banking (as
occurs for cultures passed from one laboratory to another in a
chain) results in a progressive increase in the population doubling
number and additional risk of contamination or loss of key charac-
teristics.
Cryopreservation
Automatic controlled-rate cooling apparatus provides the most
reproducible cryopreservation. Commercial equipment designed
to fit in the neck of a liquid nitrogen freezer and reduce the temper-
ature by approximately 1°C a minute is usually effective, and
homemade devices (e.g. expanded polystyrene boxes packed with
paper towelling) placed in a –70°C freezer overnight can also be
used successfully. Dimethyl sulphoxide (DMSO) at 5–10% v/v is
the most common cryoprotectant used for mammalian cells.
However, it can be toxic and may cause differentiation in some
cultures (e.g. HL-60). Glycerol (10–15% v/v) may be a suitable
alternative. Every time a batch of cells is frozen down, it is recom-
mended that one vial is resuscitated immediately to check
viability. Vials removed from the bank should be thawed rapidly
(by immersion in a water bath at 37°C) and the cell suspension
diluted in stages with prewarmed medium.
Storage
Cell stocks should be kept below –130°C as viability may be
progressively lost within a few months at –80°C. For liquid
nitrogen storage it is a legal requirement in the UK to store poten-
tially infectious material in the vapour phase. This reduces the risk
of transfer of contaminating organisms (Tedder et al, 1995) and
eliminates the hazard of liquid nitrogen penetrating ampoules
which may then explode on warming. For security, important
material (e.g. Master Cell Banks) should be divided into more than
one storage vessel, preferably on different sites.
Hazards associated with the use of liquid nitrogen include frost
bite, asphyxiation (i.e. oxygen depletion) and risk of infection and
injury due to explosion of ampoules. Plastic ampoules are
preferred as glass ampoules are more likely to explode. The
storage area should be well ventilated and where large numbers of
liquid nitrogen vessels are involved there should be an oxygen
deficiency alarm and mechanical ventilation (preferably activated
through the oxygen monitor). Appropriate personal protective
garments (e.g. insulated gloves and face masks) and equipment for
safe manual handling of nitrogen vessels should be available. Staff
should also receive training in safe working practices for the
nitrogen storage facility. Access to storage vessels should be
strictly controlled.
Freezers should be fitted with alarms and storage temperatures
regularly checked. It is recommended that levels of liquid nitrogen
in the storage vessels are recorded at least once a week. Periodic
audits for evidence of regular maintenance, monitoring and
stock control will also help ensure safety and security of storage
facilities.
Culture reagents
It is recommended that reagents and sera are purchased from
suppliers who issue certificates of analysis or results of quality
control (QC) testing with each batch of products. Reagents may be
purchased in bulk to avoid variation between batches, depending
on shelf life. Serum should be stored at –20°C, but not in frost-free
freezers as temperature cycling may crack the bottles. The shelf
life of serum is 12–18 months and longer term storage is not
recommended as any advantages gained by a single batch may be
offset by deterioration. The shelf life of single strength medium is
approximately 9–12 months, concentrated medium (10´) approxi-
mately 12–24 months and powdered medium approximately
24–36 months.
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The production of media from individual ingredients is complex
and time-consuming. Most commercial suppliers offer a custom
media service for specialized formulations. Most basic media
formulations are offered both as single strength and as 10´
concentrated liquids by suppliers. Considerable cost savings can
be achieved by using the 10´ concentrates. If concentrate is used,
this is diluted into bottles containing sterile high quality water.
Sterile L-glutamine and sodium bicarbonate are then added and
finally the pH is adjusted. The advantage of this system is that it is
quick and technically undemanding. However, several points
should be borne in mind.
a. Media concentrates have changes made to their basic formula-
tions, mainly to overcome problems of solubility
b. Precipitate is often seen on storage. If the concentrate is
aliquotted the precipitate can cause variation between bottles
c. Suppliers acidify the medium to improve solubility. This in
turn requires significant amounts of base to neutralize the
medium.
Powdered media
Powdered media produce more stable uniform products with
longer shelf lives than concentrates. However, the process does
require specialized equipment for filtration and bottling. The
following general points should be noted:
a. The powder should be free flowing and white to off-white in
colour, with no sign of dampness
b. The medium should be stirred until all the powder is dissolved.
The presence of fine particulate matter may require pre-
filtration or a change of supplier
c. Medium should always be prepared and filtered on the same
day.
Sterilization requires filtration to a pore size of 0.22 mm. Cellulose
filters are most common but polyvinylidene fluoride (PVDF)
filters should be used when protein is present in the medium.
Although a 0.22 mm filter will prevent the passage of bacteria and
fungi, mycoplasma can pass through pores of greater than 0.1 mm
in diameter. It is probably easier to screen cultures regularly for
mycoplasma contamination than to try to exclude it from a source
such as media. It may be possible to exclude viruses by ultracen-
trifugation, but this is impractical in most laboratories. Single-use
disposable cartridges are recommended as the most convenient
option for media filtration. The following basic points should be
noted:
a. The equipment should be dedicated for media production
only
b. A Class II MSC should be dedicated to media and supplement
production. If this is not possible then the cabinet should not
have been used for cell culture for at least 1 h. It must also be
cleared of all equipment and thoroughly cleaned with 70%
alcohol or non-corrosive disinfectant
c. All tubing should be clean and autoclaved before use and
connections should be securely in place
d. Sterile bottles and caps should be stacked outside the cabinet
and introduced one at a time to receive medium. Stacking
bottles within the flow cabinet will seriously compromise the
airflow, and consequently sterility
e. During bottling, representative samples should be drawn off at
regular intervals. These samples should then be incubated at
37°C for at least 10 days to check for contamination
f. Most bottled media should be stored at 4°C in the dark
g. If any sample shows contamination, the whole batch of
medium should be discarded.
Serum batch testing
Simple preliminary tests can help avoid the disastrous conse-
quences of using media, sera or supplements which do not
adequately support cell growth. Batch testing of serum should use
a range of cell lines and may include criteria for (a) cell attachment
and spreading, (b) cloning efficiency, (c) growth rates and where
appropriate (d) a functional assay. Low serum concentrations (e.g.
1%) can help highlight differences between sera. It is important to
limit carry-over of the old serum during testing, as this could mask
differences between the old and new batches. Large batches of
serum should be purchased when possible and retested before use.
Record keeping
Details of all routine and experimental procedures should be
recorded as they are generated. Good practice requires that records
must be dated, legible, clear in content and made in ink directly
into a bound laboratory notebook or onto a standard form. Enough
detail must be recorded to enable the work to be reproduced
exactly. Standard Operating Procedures (see below) should be
referenced wherever possible. Graphs, figures and photographs
should be attached to the notebook and be signed, dated and iden-
tified in such a way that, should they become detached, they could
be re-assigned to their correct place. If large numbers of print-outs
or other documents are generated, these should be annotated and
stored in a dedicated file.
Records of routine procedures carried out, such as cell counts,
cell line passaging and medium preparation can be kept on stan-
dard forms designed for the purpose. These should be stored in a
dedicated file, and cross-referenced in experimental notebooks as
required.
A certificate of analysis should be requested from the supplier
for each batch of material, and this should be stored securely for
future reference with the date received.
The originals of all experimental records remain the property of
the funding agency or laboratory, and must be lodged with them
when an experimenter leaves that laboratory or changes funding
agencies. Such records should be securely archived, with systems
in place to permit easy retrieval along with protection against
tampering.
Standard operating procedures
Procedures that are regularly carried out in a standard manner are
best documented in the form of Standard Operating Procedures
(SOP). This is a clear and detailed list of instructions, written such
that suitably trained individuals can understand and perform the
task in the intended manner. It should include details of the equip-
ment, reagents, and techniques to be used, as well as methods for
calculating and interpreting the results. Ideally, each laboratory or
organization should have its own system for the issue and tracking
of SOP. This should ensure that all copies can be tracked so that all
scientists have the most recent versions, and that they are reviewed
on a regular basis (at least once every 2 years is suggested). A
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such that only one approved version is current, reflecting best
practice. Ideally, the system should include provision for
permanent archiving of all versions and revisions of all SOP.
Equipment
Microbiological safety cabinets
Most cell culture is undertaken in a Class II MSC. These provide
protection to the operator and environment whilst maintaining a
clean working environment, but give no protection against toxic,
radioactive or corrosive materials. The effectiveness of a MSC is
dependent on its position, correct use and regular testing.
Cabinets should be sited away from doors and through traffic.
Movement in the area of the MSC will disturb the airflow and
therefore access to the area should be restricted to essential
personnel. Recommendations for siting MSC are given in BS5726
Part 2 (HMSO, 1992).
Class II cabinets which are used for genetically modified organ-
isms or primary human material should be tested every 6 months
for airflow and filter integrity and annually for operator protection.
Cabinets used for general cell culture should be tested annually.
Testing and servicing should be carried out by trained competent
personnel. Before servicing and testing is carried out, adequate
fumigation is required. This is usually performed using formalde-
hyde gas. Training is essential before this procedure is carried out.
An equipment safety certificate is normally required by servicing
engineers before testing can begin.
When performing cell culture work within a MSC it is important
to minimize the potential for contamination of the working
environment and cross-contamination between cultures. This can
be greatly assisted by the following:
a. Do not make rapid movements within the cabinet, since this
may disrupt the airflow
b. Manipulate fluids slowly and gently with the assistance of a
pipetting aid to avoid the creation of aerosols
c. Never have more than one cell line at a time in the cabinet
d. Do not overcrowd the cabinet and never obstruct the front
opening and grille
e. Organize the work area such that sterile reagents and cultures
do not come in contact with each other
f. Use caution when homogenizing tissues or cells in a MSC. If
high energy processes such as sonication are used the particles
cannot always be assumed to be contained by the cabinet
airflow
g. Clean and decontaminate the cabinet inner surfaces after each
work session and periodically decontaminate the tray under the
MSC working surface
h. When working in a MSC, a Bunsen or similar burner must not
be used (unless absolutely required for a specialized proce-
dure) as they disrupt the airflow pattern, thus reducing the
cabinet’s effectiveness, and they pose a fire risk.
Incubators
Most modern incubators are humidified and used with an atmos-
phere typically containing 5% carbon dioxide. The following
points should be considered:
a. Humidifying water should contain an antibacterial/antifungal
agent as per manufacturer’s recommendations.
b. Incubators should be calibrated for temperature and gas
composition
c. Carbon dioxide levels should be checked monthly using a
Fyrite apparatus (marked deviations will be evident as a
change in pH of the medium)
d. Every 6–8 weeks the incubator should be emptied, dried and
cleaned with 70% alcohol or equivalent non-corrosive disin-
fectant. All shelves should be similarly removed and cleaned
e. Individual trays on which culture flasks can be easily moved in
and out of the incubator should be used. These may be cleaned
more frequently and help reduce contamination from spillages
f. Incubator temperatures and contents should be inspected daily
g. Spillages must be dealt with immediately
h. All infected plates, dishes or flasks must be removed immedi-
ately and disposed of appropriately
i. Incubators must only be used for cell culture and not for incu-
bating microorganisms or biochemical samples
j. Gassed incubators should be attached to a suitable cylinder
change-over unit
k. Cylinders used to supply gas should be securely anchored
l. Cylinders should be clearly labelled and have the correct regu-
lating valves attached
m.Cylinders should be changed by trained personnel wearing
suitable high impact eye protection.
Autoclaves and sterilizing ovens
Autoclaves are used for sterilizing equipment and consumables.
Correct function and safe operation are described in the HSE
guidelines (Health and Safety Executives, 1990). Autoclaves must
be covered by insurance, which will necessitate an annual inspec-
tion. It is essential that proper protective clothing (including a face
visor and heat-proof gloves) are used, and the autoclave not
opened until the temperature has fallen below 50°C. Autoclaving
of liquids in glass containers can present particular hazards.
It is essential that regular checks are made to ensure that the
autoclave is operating at the required temperature and pressure.
Qualitative indicators (e.g. autoclave tape) are useful to distinguish
items that have been autoclaved from those which have not.
They do not, however, provide any guarantee that a full autoclave
cycle has occurred and hence that the item is satisfactorily
sterilized.
Water purifying apparatus
The use of high purity water is essential for successful cell culture.
Reverse osmosis followed by passage through mixed bed ion
exchange resins and carbon and microspore filtration provides
pyrogen-free water of tissue culture grade. Water should be
measured for pH and conductance and can be tested commercially.
Serum can protect cells from toxins and consequently the use
of high purity water is critical in low protein or serum-free
conditions. The purity of water is only maintained if it is placed in
suitably clean bottles dedicated to storage of water or media.
SECTION 4: CELL LINE PROBLEMS:
IDENTIFICATION AND ELIMINATION
Cultures should always be examined under an inverted phase
microscope before any manipulations are performed, and
frequent assessments should be made of the viability of the cell
population.
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Whenever a rapidly-growing, continuous cell line is maintained in
a laboratory there is a risk that it may cross-contaminate other,
more slowly-growing lines. There is a long history of this
problem, highlighted in the 1960s and 1970s (Gartler, 1967;
Lavappa, 1978), but now often ignored. Few authors using cell
lines such as KB, Chang liver, or Hep-2 acknowledge that they are
cross-contaminated with HeLa cells, and probably carry none of
the original cell lineages. Similarly, some human breast and
bladder cancer cell lines with a variety of names are in fact MCF-
7 and T24 respectively. This may have limited importance if the
property under examination is cell line-specific and intrinsically
important, but if comparisons are to be made between cell lines or
if extrapolations are made to the tissue of origin or a particular
class of cell lines, then interpretation of the data can only be made
if the target cell lines are correctly identified.
Identification of cell line cross-contamination
The advantages of the methods available for determining the
origin and uniqueness of a cell line are listed in Appendix 4.
It is recommended that a reproducible DNA fingerprinting or
profiling method is routinely adopted for all cell lines within the
laboratory.
Prevention of cell line cross-contamination
A problem arises when a small number of cells from a rapidly
growing cell line are inadvertently transferred into a culture of
more slowly growing cells. Such transfer can occur by a variety of
routes such as the accidental touching of a pipette on the neck of a
bottle of medium or some other common reagent, or by the pres-
ence of an aerosol in the MSC at a time when flasks are uncapped.
In a theoretical example, a single cell from a line with a popula-
tion doubling time of 12 h is transferred into a culture of 105 cells
of a cell line with a population doubling time of 48 h. By the time
the slow-growing cell line has expanded from 105 to 3.2 ´ 106 cells
(i.e. 5 doublings or 10 days), the rapidly growing cells will have
doubled 20 times (i.e. from a single cell to 106 cells), and hence
comprise nearly 25% of the total cell population. After one further
passage, the rapidly growing cells will predominate.
Because of the problem of cross-contamination, derivation of
new cell lines should allow for future authentication by storing
samples of tissue or DNA from the source individual for subse-
quent DNA fingerprinting. Cell lines new to a laboratory should be
developed into frozen stocks and typed. Change in cell behaviour
or morphology may indicate a cross-contamination and constant
vigilance and attention to good tissue culture practice are essential.
Simple precautions must be taken to minimize the possibility of
cross-contamination, including:
a. Only one cell line should be used in a MSC at any one time.
After removal of the cells from the cabinet, it should be
swabbed down with a suitable liquid disinfectant and the
cabinet run for 5 min before the introduction of another cell
line
b. Bottles or aliquots of medium should be dedicated for use with
only one cell line
c. The formation of aerosols must be kept to a minimum
d. Regularly return to frozen stocks (except where essential,
never grow a cell line for more than 3 months or ten passages,
whichever is the shorter period)
e. All culture vessels must be carefully and correctly labelled
(including full name of cell line, passage number and date of
transfer), as must storage containers.
Mycoplasma contamination
Mycoplasmas are small, self-replicating prokaryotes (0.3–0.8 mm
diameter), lack a cell wall and have the ability to cytoadsorb onto
host cells. Mycoplasma is one of the most serious forms of cryptic
contamination and its presence is not detected unless appropriate
tests are made or until some aspect of cell behaviour is noticed to
have changed. The consequences of mycoplasma contamination
have been documented (McGarrity et al, 1984), influencing almost
every aspect of cell biology. Between 15 and 50% of cell lines
submitted to cell banks are contaminated with mycoplasma.
Laboratories which do not test for mycoplasma probably harbour
contaminated cell lines and may even have their entire stocks con-
taminated, as mycoplasma spreads readily among cell lines via
reagents and media, the operator and the work surface. The pres-
ence of mycoplasma may invalidate the results obtained with that
culture. The presence of mycoplasma-infected cultures can result
in the shut-down of the entire laboratory until the infection can be
eliminated, whereupon complete restocking is required.
Identification of mycoplasma contamination
The origin of contamination is usually traced to mycoplasma
present in animal (bovine) serum or to human oral mycoplasma
transferred by droplet infection during cell culture. Methods for
detecting mycoplasma species are summarized in Appendix 5.
The simplest test for the detection of mycoplasma in cultures is
the use of a fluorescent dye which binds directly to DNA causing
fluorescence (e.g. Hoechst 33258) which can be seen by fluores-
cence microscopy. Mycoplasma-positive cells will show intense
fluorescent spots on the plasma membranes or show filaments
which may be absorbed onto the cells. Uncontaminated cells show
only brightly fluorescent cell nuclei. The technique is rapid (less
than 30 min), but requires heavy contamination (106 mycoplasma
ml–1) to produce a clear positive result. If however, the suspect
cells are co-incubated for 2–4 days with an ‘indicator’ cell line
(such as 3T3) which is particularly suitable for demonstration of
positive staining, then sensitivity can be substantially increased.
Microbiological culture techniques are available that operate at
a greater sensitivity, but it can take up to 21 days to obtain a result,
a positive control is needed, and the result may require expert
interpretation. A variety of polymerase chain reaction (PCR)
based methods are available, some of which have been utilized as
commercially available detection kits. It is recommended to use a
combination of DNA staining and a PCR-based method once
every 3 months for all growing cultures in the laboratory and for
every new cell line as it enters the laboratory. In addition, all
Master and Working Cell Banks should be tested at the time of
freezing.
Prevention of mycoplasma contamination
Quality control and good working practice will reduce potential
problems. It is important that frozen stocks are created immedi-
ately after testing and re-tested before distribution. If cells are
cultured for more than 3 months after testing, they should be re-
tested. Regulatory bodies now insist that cell cultures used for the
production of reagents for diagnostic kits or therapeutic agents are
free from mycoplasma infection. Also, some scientific journals
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culture work reported in those journals is carried out with
mycoplasma-free cells.
Normally, when contamination with mycoplasma is apparent,
the recommendation would be to discard the cultures and start
again. If necessary, and only if the contamination is not extensive,
then it is often possible to rescue the cells by treatment with one of
the commercially available antibiotics. This must only be consid-
ered for a remedial action, not as a routine supplement to growth
media (and thereby a substitute for good cell culture practice).
Contamination by other microorganisms
With correct working practice it is not necessary to use antibiotics
when working with established cell lines, and the use of antibiotics
should be discouraged. Microbial contamination may be overt, and
hence act as a signal to discard the culture, but if antibiotics are
used, contamination may be repressed but not eliminated. Such
cryptic contamination may co-exist with the cell culture and only
appear when the culture conditions change, or a truly resistant
organism appears.
A cautionary note is that antibiotics and antifungal agents act
by inhibiting biochemical functions of the organism, and conse-
quently may alter the outcome of experiments. For example,
amphotericin B is a membrane active agent and may therefore
interfere with any mammalian cell experiments involving
membrane trafficking or intercellular signalling.
Bacteria and fungi
If cells are cultured in antibiotic-free media as recommended,
contamination by bacteria, yeast or fungi can usually be detected
by an increase in turbidity of the medium and/or a decrease in pH
(yellow in media containing phenol red as a pH indicator). It is
recommended that cells are inspected daily, and must always be
examined under an inverted phase microscope before use in an
experiment.
The two methods generally used for bacterial and fungal detec-
tion are microbiological culture in special media and direct obser-
vation using Grams stain. It is recommended that the help of a
hospital microbiology laboratory is sought with identification and
sensitivity testing.
If a cell culture is contaminated with bacteria or fungi, then the
best method of elimination is to discard the culture and obtain
fresh stock cultures or new supplies. In the case of irreplaceable
stocks, it will be necessary to use antibiotics. The more antibiotics
that are tested, the more chance there is of finding one that elimi-
nates the infection. However, if the cells have been routinely
grown in media supplemented with antibiotics (which is not
recommended), it is almost certain that the contamination will be
with organisms that are already resistant to this and some other
antibiotics.
To eliminate infection, the cells should be cultured in the pres-
ence of the antibiotic for at least three passages. If the contamina-
tion appears to be eradicated, then the cells should be cultured in
antibiotic-free medium for 1 month before re-testing.
Viruses
As long as serum is used to supplement media and natural trypsin
is used in subculture, there will always be a risk that endogenous
infections in the source of the reagent will infect the culture. The
source of viral contamination can be from the tissue from which
the cells are derived (e.g. HIV from Kaposi’s sarcoma cells, EBV
from lymphoma cells). Alternatively, contamination can be
derived from growth media from other infected cultures or, as a
more remote possibility, from laboratory personnel. Another route
of infection can be during passage of cells in experimental
animals. This is important when considering the use of cell lines
for implantation of xenograft tumours. Not only do the cells to be
implanted need to be free from contamination by extraneous
viruses, but also the animals into which the transplant is to be
made should not harbour viruses that could affect the growth and
response to therapy of the cells under study (UKCCCR, 1998).
As with mycoplasma, elimination is difficult. However, what is
worse, there are no simple universal diagnostic tests to identify
viral contamination. To identify viruses necessitates screening
with a wide panel of immunological or molecular probes. As yet,
such testing is restricted to human pathogens such as HIV and
hepatitis B, and few laboratories screen for animal viruses on a
routine basis.
Transmissible spongiform encephalopathy
Transmissible spongiform encephalopathy (TSE) (including what
is known as bovine spongiform encephalopathy, BSE or mad cow
disease) is unlikely to be present in cancer cells or tissue culture
products. However, a risk of exposure must be regarded as poten-
tially present, particularly since all the routes of transmission have
not been identified. Some regulatory authorities now demand that
serum used in the production of pharmaceutical, veterinary, and
sometimes diagnostic products can only be obtained from speci-
fied countries of origin where BSE has not been diagnosed. Some
countries, including the USA, will only allow import of cells that
have been cultured in media containing serum from BSE-free
areas.
Genetic instability and phenotypic drift
Two other major problems which can affect the utility of cell lines
are genetic instability and phenotypic drift. Wherever possible it is
recommended that records are kept of the length of time a cell line
has been kept in culture. This is routinely achieved through the
recording of passage numbers from the time of initial establish-
ment. The use of continuous cell lines at low passage number
(less than 50 passages from the time of immortalization) is
recommended.
Genetic instability
In general, the karyotype of cell lines is remarkably stable,
provided that the culture conditions do not change. However, the
chromosomal content of most continuous cell lines is both aneu-
ploid (abnormal chromosome content) and heteroploid (variable
chromosome content within the population). Many cancer cell
lines have defects in p53 and other genes that monitor and repair
DNA damage, resulting in an increased mutation frequency.
Hence, the genotype of continuous cell lines can change with time
and cell lines should not therefore be maintained for extended
periods of time in continuous culture. Within a laboratory,
provided culture conditions do not change, cell lines are remark-
ably stable. However, between laboratories, cell lines are subject
to selective pressures, and genetic and phenotypic changes are
often seen, for example in stocks of the human breast cancer cell
line MCF-7.
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normal chromosomal content, at least as far as can be judged from
the karyotype. Most normal human cell lines will senesce and
cease proliferation without major heritable changes in the geno-
type. In contrast, rodent cell lines, particularly mouse lines,
become unstable and immortalize readily. Immortal cell lines,
such as 3T3, can retain their normal (untransformed) growth char-
acteristics provided that the recommended maintenance proce-
dures are adhered to. In particular, they should not be allowed to
become confluent, but should be subcultured from mid-log phase,
and replaced regularly from frozen stock. They require constant
monitoring to ensure that transformed variants, readily detected
morphologically by their more retractile appearance and lack of
contact inhibition, do not overgrow.
Phenotypic instability
Lack of expression of the differentiated properties of the cells of
origin is a major recurrent problem. This can be due to selection of
the wrong cell lineage in inappropriate culture conditions. For
example, a disaggregated skin biopsy will ultimately give rise
to a fibroblastic population which overgrows the epidermal
keratinocytes, unless selective conditions are used. However, even
under selective conditions, the need for propagation stimulates cell
proliferation rather than differentiation. This process can either
select undifferentiated cells or can lead to a loss of differentiated
characteristics. In some cases, such as fibroblasts or endothelial
cells, this is due to dedifferentiation, but in others, such as
mammary epithelium, it is probably due to propagation and
expansion of the progenitor cell compartment, which lacks the
differentiated characteristics.
Examination of processes which depend on the expression of
the in vivo phenotype, whether normal or neoplastic, may require
modifications to culture conditions (e.g. high cell density, growth
factors, low serum, position at the air–liquid interface, heterolo-
gous cell interaction, extracellular matrix) which usually are
incompatible with cell proliferation. Hence different conditions
need to be defined for culture of a cell line dependent on whether
cell proliferation or cell differentiation is required.
To minimize genotypic and phenotypic variation of a cell line
within and between laboratories, it should be expanded and frozen,
and used to provide the seed stock for future work. Cells should be
replaced from frozen stocks after a maximum of ten passages or 3
months continuous culture (whichever is the shorter). It is impor-
tant and probably essential for comparative purposes that different
laboratories using the same cell line should match their culture
conditions as closely as possible.
SECTION 5: CELL LINE DISTRIBUTION
Introduction
Transferring a cell line between laboratories may involve transport
within a city or between continents. Therefore, consideration will
have to be given to the condition of the cells, the means of trans-
port and the legal requirements. Cell lines may be transported
either as growing cultures or as vials of frozen cells.
Within the UK and Western Europe, use of a courier service
should ensure delivery within 48 h to most destinations. Delivery
to most places outside of Europe should be possible within 96 h
and this is compatible with sending growing cultures. However, it
is impossible to guarantee that packages have remained under
appropriate conditions (e.g. temperature, vibration-free)
throughout the transport period. If frozen vials are sent, the fact
that solid carbon dioxide remains within the package should be
sufficient to ensure that transport conditions have been
acceptable.
Some couriers will not accept boxes containing solid carbon
dioxide for transportation and hence enquiries regarding this point
should be made in advance.
Transport containers
Cultures of adherent cells growing in flasks should not be sent
with the usual volume of medium (e.g. 5 ml in a 25 cm2 flask).
Movement of the package during transport will result in excessive
frothing and cell destruction. One method is to fill the flask
completely with medium at the correct pH and hence totally
exclude all gas. Disadvantages of this procedure are that the flask
is heavy, there is a considerable volume of medium to leak if the
flask is broken, and cultures may subsequently become infected
because of medium around the neck and cap of the flask. An alter-
native method is to remove all except a few drops of medium from
the flask, gas with the appropriate mixture, and seal the flask. The
small volume of medium is sufficient to keep the cells moist but
insufficient to allow frothing to occur, and cells remain viable for
at least 72 h.
For suspension cultures or cells which grow as floating aggre-
gates, 2 ml plastic freezing vials are suitable containers for trans-
port. Cells in medium should be transferred to the vial in a volume
of 1.0–1.5 ml and medium then added drop-by-drop to fill the vial
before replacing the screw cap. Because of their size, such vials
can be sent in small padded envelopes.
Insulated boxes suitable for transport of frozen vials of cells are
used by various laboratory supply companies for distribution of
frozen reagents. Those used by Amersham International for labile
radioisotopes are of suitable thickness and dimensions. Such
boxes typically have 5 cm thick walls with a central cavity of
15 ´ 15 ´ 15 cm. This can be filled with solid carbon dioxide,
which will maintain temperature for a maximum of 4 days.
Practicalities
Experience dictates that adherence to the following points will
increase the probability of successful transfer:
a. Communicate fully with the carrier and the recipient in
advance. Be sure that they both know the collection time and
the anticipated delivery time. Exchange telephone/fax numbers
for use should problems arise
b. Make sure that the recipient knows what type of containers are
being sent and the state of the cells. Make sure that they know
what to do with the cells when they arrive, that they have the
correct medium available, and that they are familiar with the
growth characteristics of the cells
c. Ask the recipient to notify you when the cells arrive or when
the cells have failed to arrive within a reasonable period
d. Send packages on a Monday to improve the chance of a
weekday delivery
e. Ask the recipient to establish, as a high priority, their own
frozen stock of the cells so that repeated transport is not
needed.
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Various regulations must be complied with when sending cells to
other laboratories. These include legal requirements of various
countries and regulations established by individual carriers. It is
strongly recommended that full details of these are obtained before
any transport is attempted. Regulations concerning the transport
of potentially dangerous goods are published by the International
Air Transport Association (IATA) and updated annually.
Further information can be found on the IATA web site
(http://www.iata.org/cargo/dg/dgr.htm).
It is beyond the scope of these Guidelines to spell out in detail
the full regulations. However, the following points may be useful
in providing general guidance:
Within the UK
The precise requirements for sending cells via the postal service in
the UK are currently being revised. It is therefore recommended
that the local Customer Service Centre of the Royal Mail must be
contacted for advice prior to sending biological material by post.
Import to the UK
While there are few restrictions on the movement of cell cultures
within the European Community, importation of certain animal
cells from other countries into the UK requires a permit from the
Ministry of Agriculture, Fisheries and Food (MAFF) at the Animal
Health Disease Centre, Tolworth, Surbiton, Surrey KT6 7NF: This
is particularly important for cells from agricultural species where
there is a serious risk of importing non-endemic viruses (e.g. hog
cholera virus in pig cell lines). It is strongly recommended that
current regulations be checked, especially if there are doubts about
the legality of the importation.
Export from the UK
Apart from the USA, few countries have specific regulations
regarding the import of cell lines and hence sending cells abroad
should not present major problems. However, if material is classi-
fied as ACDP category 2 or above (HMSO, 1995), special condi-
tions apply and the sender must undergo formal training. It is
recommended that the cell line(s) are sent by courier service and
that the contents of the package must be clearly labelled on
the ‘shipper’s declaration’ as ‘biological material for research
purposes’.
Sending cells to the USA
Many people have experienced difficulties in sending cells to the
USA. However, problems can be minimized by strict adherence to
the following advice:
It is obligatory for the importation of cell lines or their products
into the United States that an application is made for a Veterinary
Permit from the US Department of Agriculture prior to shipment.
To obtain a permit the forms VS 16-3 and VS 16–7 are requested
by the recipient of the cells from the USDA (USDA, APHIS,
Veterinary Services, National Center for Import and Export, 4700
River Road, Unit 40, Riverdale, MD 20737-1231, USA: Tel: +1-
301-734-3277; Fax: +1-301-734-8226). The recipient must
complete the forms and return them to the USDA address (faxed
copies are accepted) with copies of other relevant information
required. The main points of information required are:
a. The animal the product was derived from
b. The storage fluid (e.g. saline solution, bovine serum)
c. Full description of the culture including the origin of serum
used in culture (other supporting documentation of the source
of serum may be required and use of serum originating in the
US can help)
d. The history of the product
e. The intended use
f. The country of origin
g. The recipient’s company name, contact name and telephone
number
h. The correct temperature for storage.
Upon receipt of a satisfactorily completed form, the Department of
Agriculture will issue a permit (VS form 16-16A). A copy of this
permit should be taped to the outside of the package. This should
expedite passage of the package through US customs.
SECTION 6: TROUBLESHOOTING
Even with full attention to these Guidelines and/or other estab-
lished rules of good practice, every laboratory will, from time to
time, encounter problems ranging from widespread fungal conta-
mination to quite subtle deviations from normal patterns of cell
growth. When such problems occur, a logical and systematic
approach should be taken to identifying and removing the causes.
Without good background information, assessment of a problem
can be unnecessarily difficult or impossible. Careful logging of
reagent batch numbers used to make each bottle of medium may
often seem pedantic and time-consuming, but can prove invaluable
when problems occur. Similarly, careful documentation of the
normal behaviour of a cell line provides essential background
information. This can include records of cell counts at subculture
and occasional photographs of growing cultures.
The following general approach to troubleshooting may prove
useful:
a. Once the existence of a problem is suspected, it is important to
define its characteristics and inform all those who may be
affected
b. If the nature of the problem is readily identified (e.g. a defec-
tive incubator), make sure by appropriate means that its exis-
tence is known (e.g. a large notice on the incubator) and that
the person responsible is dealing with the problem
c. Less obvious problems will need a more comprehensive
survey of the facts. This may be facilitated by a meeting of all
those involved, as even apparently quite trivial observations
may be relevant
d. Once the problem is identified, it should be possible to draw
up a list of possible causes in order of probability
e. It is often useful to ask ‘what is new?’ in terms of reagents or
procedures which may coincide with the problem. Be aware,
however, of possible time displacements such as the effects of
a minimally substandard medium batch only becoming mani-
fest after several cell generations, with some cell lines being
more sensitive than others
f. When switching to a new batch of any medium component
(including serum), even though this has been batch-tested,
retain a reasonable amount of the old batch for some period of
time. This will allow head-to-head testing should problems
arise when the new batch is introduced
g. With problems of deficient cell growth and/or unusual appear-
ance, the problem may lie with the cells, the growth medium,
the growth environment or some combination of these. Clues
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lines are affected (do they share an incubator?, do they have a
common medium?)
h. If a particular cell line is affected, and tests for contamination
(bacteria, mycoplasma) are negative, a vial of the cell line
should be taken from frozen stock and the old and new cells
tested head-to-head over several passages. If the old cells
continue to do badly and the new cells grow normally, then the
old cell stock should be discarded and the new stock used for
future work. If both stocks do badly then the problem probably
lies elsewhere. (Virtually all cell lines take a period of time to
recover from being frozen, so this needs to be taken account of
when comparing growth patterns.)
i. Where a problem with the medium appears to be present, a
series of tests should be set up in which head-to-head growth
comparisons are made in different media where only one
medium component at a time is changed. Although serum and
basic medium may be the most obvious sources of problems,
other components including water, glutamine and antibiotics
are also candidates
j. If a problem component is identified, the finding should be
discussed with the supplier who may be able to state that the
batch has been used by many other laboratories without prob-
lems or (occasionally and off-the-record) that there may be a
problem with a batch
k. In the experience of many workers, problems sometimes are
never satisfactorily solved, but the cells begin, after some time,
to resume normal growth. Such problems may, however, recur
and the combined experience of the first and second episodes
may be helpful in further investigation.
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APPENDIX 1: DEFINITIONS OF TERMS
FREQUENTLY USED IN TISSUE CULTURE
These guidelines use terms as defined by Schaeffer (1990).
A primary culture refers to a culture from the time of isolation
until its first subculture.
A cell line is formed when a primary culture is subcultured. A cell
line may be finite (survives for a fixed number of population
doublings, usually around 40–60, before senescing and ceasing
proliferation) or continuous (immortal, over 200 population
doublings).
The use of the term ‘established’ for a continuous cell line is
discouraged because it is ambiguous.
Cell strains are cell lines which have been purified by physical
separation, selection or cloning, and which have specific defined
characteristics, e.g. BHK-21-PyY, anchorage-independent cells
cloned from the BHK-21 cell line following transformation with
polyoma virus.
Cloning is the generation of a colony from a single cell, and
subculture of such a colony would give rise to a cell strain.
Because of potential confusion with molecular cloning, this term is
probably better modified to cell cloning.
Immortalization is the indefinite extension of lifespan in culture,
usually achieved by the introduction of a viral gene, but already
acquired by some cancer cells.
Transformation is a heritable change involving an alteration in the
genotype, usually subsequent to immortalization. It is best
reserved to describe an alteration in growth characteristics associ-
ated with malignancy (anchorage independence, loss of contact
inhibition and density limitation of cell proliferation, tumori-
genesis in vivo).
APPENDIX 2: PATIENT CONSENT FORM:
POINTS TO CONSIDER
a. The donor is under stress and is being asked to help you. Your
request is an additional factor which may add to that stress
b. The Patient Consent Form and associated Patient Information
Sheet (necessary for most studies) should be written in concise
and explicit language that anyone can easily understand,
explaining clearly the need for the specimen, the overall objec-
tive of the research and why it is important (in lay terms)
c. The additional discomfort or inconvenience which will occur
if the donor agrees to your request should be clearly explained
d. The donor should be told clearly that there is no obligation
whatsoever to participate in your research
1506 UKCCCR
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should be told clearly what financial benefit might be gained
from the research and a waiver to commercial rights should be
requested
f. The donor should be told that the research has been approved
by the local Ethics Committee (give date and reference)
g. All forms should be marked Confidential
h. It should be made clear that confidentiality will be assured, but
if not (e.g. familial studies) indicate who will have access to
the clinical data and how access will be controlled
i. Fully informed consent means that the person should have
access to all information relating to the use of the specimen
provided. The details may be covered in a Patient Information
Sheet, but the name(s) and phone number(s) of investigators
should be included on the form and sheet, so that the donor can
obtain further information if needed
j. The information sheet and consent form must be printed on
official headed notepaper.
k. Consent forms should address the following questions:
Have you read the information sheet about this study?
Have you had an opportunity to ask questions and discuss the
study?
Have you received satisfactory answers to all your questions?
Have you received enough information about this study?
Which doctor have you spoken to about this study?
Do you understand that you are free to withdraw from this study
(i) at any time, (ii) without giving a reason and (iii) without
affecting your future medical care?
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APPENDIX 3: CELL CULTURE BANKS
Collection Address Web site
American Type Culture 10801 University Blvd, http://www.atcc.org
Collection (ATCC) Manassas, VA 20108-
1549, USA
Coriell Cell Repository 401 Haddon Avenue, http://locus.umdnj.edu/ccr
Camden, NJ 08103,
USA
Deutsche Sammlung Mascheroder Weg 1b, http://www.dsmz.de
von Mikroorganismen D-38124 Braunschweig,
und Zellkulturen Germany
(DSMZ)
European Collection of CAMR, Salisbury, Wilts http://www.camr.org.uk
Animal Cell Cultures SP4 0JG, UK
(ECACC)
Japanese Collection of 1-1-43 Hoen-Zaka, http://cellbank.nihs.go.jp
Research Bioresources Chuo-Ku, Osaka 540,
(JCRB) Japan
RIKEN Gene Bank 3-1-1 Koyadai, Tsukuba http://www.rtc.riken.go.jp
Science City, Ibaraki
305, Japan
APPENDIX 4: METHODS FOR CELL LINE IDENTIFICATION
Technique Advantages Disadvantages
DNA fingerprinting Specific identification of Requires high degree
Multilocus repeat origin. Can be used to of technical
sequences measure genetic reproducibility. No gene
relatedness identification.
DNA fingerprinting Rapid with high degree Requires careful
Random primers of specificity validation for
reproducibility. No gene identification.
DNA profiling by PCR Rapid, reproducible Several loci must be
of single loci and easy to read. Allele analysed for
frequencies known unequivocal identification within
species. Primers specific for each
species need to be included.
Isozyme typing Rapid identification of Low sensitivity.
species. Standardized Several isozymes must
kits available be analysed for unequivocal
identification within species
Karyotyping Detection of marker Requires relatively
chromosomes may high degree of skill in
allow unique technique and
identification of interpretation
individual cell lines1508 UKCCCR
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APPENDIX 5: MYCOPLASMA DETECTION METHODS
Method Sensitivity Advantages Disadvantages




Indirect DNA High Amplifies Indirect and thus
stain on contamination, more time-
indicator cells so easy to consuming
(e.g. 3T3) interpret
Broth and agar High Sensitive Relatively slow
culture and may require
expert
interpretation
ELISA Moderate Rapid Limited range of
species detected




may be needed to
distinguish
species
Positive and negative controls should be included
SUMMARY
Section 1: Derivation of a new cell line
1A Obtain permission from the Local Research Ethics
Committee (human material) or Animal Welfare
Committee (animal material).
1B Clarify ownership and ethical issues, bearing in mind
possible future commercial exploitation.
1C Only transfer the cell line to other laboratories after
completion of a ‘Materials Transfer Agreement’.
1D Document the clinical details of the donor.
1E Store tumour and normal tissue and use to confirm cell line
origin by DNA fingerprinting or profiling.
1F Document all reagents, culture conditions and passage
dates during derivation of the cell line.
1G Ensure that the cell line has a unique, unambiguous
designation.
1H Freeze down an initial bank of cells as soon as possible.
Section 2: Cell line acquisition
2A Cell lines being brought into the laboratory should go
through a quarantine procedure.
2B Characterize the new line to confirm its identity and
freedom from infection.
2C Cell lines acquired from established culture collections
are unlikely to carry bacterial, fungal or mycoplasma
contamination, but in most cases there is no guarantee
that the cell line is not cross-contaminated.
2D Freeze down a bank of cells as soon as possible.
Section 3: Cell line practice
3A Ensure that you are familiar with local Safety Rules as
established by the institution’s Biological Safety Officer.
3B Handle clinical specimens as potentially infected with HIV,
hepatitis or other hazardous agents.
3C Establish correct disposal routes for all types of laboratory
waste before starting a procedure.
3D Ensure that staff have received adequate training before
their work commences.
3E Establish a Master Cell Bank and a Working Cell Bank
for each cell line in use. Determine rules of access to these
cell stocks.
3F Replace working cell stocks from the bank at regular
intervals (ten passages or at 3 months, whichever is
shorter).
3G Purchase media and reagents (especially serum) from
established sources.
3H Keep medium preparation entirely separate from
procedures involving living cells.
3I Keep full and careful records of all batch numbers of
reagents and media.
3J Establish ‘Standard Operating Procedures’ for all routine
laboratory procedures.
3K Ensure that all items of laboratory equipment (cabinets,
incubators, autoclaves, water filtration units) are properly
serviced and are working within prescribed limits.
3L Inspect the cells under an inverted phase microscope
before use. For routine culture, inspect cells regularly
(at 2- to 3-day intervals as a minimum).
Section 4: Cell line problems
4A Handle cell lines entirely separately so as to minimize the
risk of cross-contamination.
4B Do not add antibiotics to the culture medium.
4C Carry out regular tests for mycoplasma contamination,
especially immediately before establishing a frozen stock.
Subsequently check for contamination on a thawed sample
from the frozen stock.4D Cells carrying infection with bacteria, fungi or
mycoplasma should be discarded unless some unique
property requires that ‘clean-up’ be attempted. Such
procedures are sometimes effective, but a long time will be
needed to ensure that contamination has successfully been
eliminated.
4E Be aware of the possibility of ‘phenotypic drift’ during
repeat passaging of cell lines. Establish a pattern of routine
reversion to frozen stock so as to minimize the effect
(see 3F).
Section 5: Cell line distribution
5A Only transfer cells after full discussion of all details with
the recipient.
5B Ensure that the recipient has all the necessary information
to handle the cells correctly following receipt.
5C Determine the regulations of individual courier services
before attempting to send cells outside the UK.
5D Only send cells to the USA after obtaining clearance from
the US Department of Agriculture.
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